Key result
Novel cancer therapeutics, including tyrosine kinase inhibitors and immunotherapies, are associated with diverse cardiovascular toxicities such as vascular disease, hypertension, and arrhythmias.
The field of cardio-oncology must expand beyond anthracycline-induced heart failure to recognize and manage the diverse cardiovascular toxicities associated with novel targeted and immunologic cancer therapies.
Answers are grounded in this paper and cite their sources.
Clinicians should monitor for vascular, hypertensive, and arrhythmic toxicities with novel cancer therapies; extends cardio-oncology scope but leaves optimal management strategies open.
Dr Michael Fradley discusses the cardiac implications beyond anthracyclines and heart failure Over the last several decades, the survival rates for many cancers have increased dramatically, largely driven by improved screening modalities and the development of novel cancer treatments including targeted and immunologic therapies. Despite these advancements, cardiovascular toxicity is a commonly observed complication of many of these treatments. As a result, the field of cardio-oncology has developed at a rapid pace. Cardio-oncology is a multidisciplinary specialty aimed at managing and preventing cardiovascular disease in cancer patients and survivors.1 Initially, cardio-oncology was focused on cardiomyopathy and congestive heart failure associated with anthracyclines, a class of chemotherapeutics used to treat a variety of cancers including breast, sarcoma, leukaemia, and lymphoma.2 As the field of cardio-oncology has grown, there is increased recognition that cardiotoxicity is not limited to just anthracyclines and heart failure; instead novel cancer therapeutics are associated with a variety of cardiac complications including vascular disease, accelerated hypertension, and arrhythmias. It is important for the cardio-oncologist to possess a broad knowledge of these agents and their toxicities in order to provide optimal care to patients. With improved understanding of cancer biology, the landscape of cancer therapeutics has changed dramatically. For example, abnormal cell signalling pathways have been implicated in many different cancers, often due to overexpressed or mutated protein kinases impacting the amino acid tyrosine.3 There is also data demonstrating that certain cancers are particularly dependent on proteasomes (multienzyme complexes that play a key role in protein degradation and homeostasis) for survival and proliferation.4 As such, the development of tyrosine kinase inhibitors (TKIs) and proteasome inhibitors (PIs), have led to significant improvements in the treatment of many liquid and solid tumours. More recently, immunomodulatory drugs (IMiDs) and other immunotherapies that harness the body’s own immune system to appropriately identify and destroy abnormal cancer cells have demonstrated promising results.5 Nevertheless, these treatments often have off-target effects leading to significant cardiac toxicity including stroke, myocardial infarction, accelerated hypertension and arrhythmias that can limit their use in some patients (Table 1). Cardiotoxicity Hypertension Vascular disease (including coronary artery, cerebrovascular, and peripheral arterial disease) Arrhythmias (including atrial fibrillation) QT prolongation Cardiomyopathy/heart failure Metabolic abnormalities (hyperlipidemia, hyperglycemia) Hypertension Cardiomyopathy/heart failure Venous thromboembolism Arterial thromboembolism (including myocardial infarction and stroke) Myocarditis Arrhythmias (including atrial fibrillation) Myocardial ischemia Hypotension Hypertension Vascular disease (including coronary artery, cerebrovascular, and peripheral arterial disease) Arrhythmias (including atrial fibrillation) QT prolongation Cardiomyopathy/heart failure Metabolic abnormalities (hyperlipidemia, hyperglycemia) Hypertension Cardiomyopathy/heart failure Venous thromboembolism Arterial thromboembolism (including myocardial infarction and stroke) Myocarditis Arrhythmias (including atrial fibrillation) Myocardial ischemia Hypotension aCardiotoxicity profiles will vary between individual pharmaceuticals included within each cancer therapeutic class. Cardiotoxicity Hypertension Vascular disease (including coronary artery, cerebrovascular, and peripheral arterial disease) Arrhythmias (including atrial fibrillation) QT prolongation Cardiomyopathy/heart failure Metabolic abnormalities (hyperlipidemia, hyperglycemia) Hypertension Cardiomyopathy/heart failure Venous thromboembolism Arterial thromboembolism (including myocardial infarction and stroke) Myocarditis Arrhythmias (including atrial fibrillation) Myocardial ischemia Hypotension Hypertension Vascular disease (including coronary artery, cerebrovascular, and peripheral arterial disease) Arrhythmias (including atrial fibrillation) QT prolongation Cardiomyopathy/heart failure Metabolic abnormalities (hyperlipidemia, hyperglycemia) Hypertension Cardiomyopathy/heart failure Venous thromboembolism Arterial thromboembolism (including myocardial infarction and stroke) Myocarditis Arrhythmias (including atrial fibrillation) Myocardial ischemia Hypotension aCardiotoxicity profiles will vary between individual pharmaceuticals included within each cancer therapeutic class. There is increased focus on the vascular toxicities associated with certain TKIs and IMiDs primarily used to treat chronic myelogenous leukaemia (CML) and multiple myeloma (MM). These toxicities include both arterial and venous thrombo-embolic events and accelerated hypertension, causing significant cardiovascular morbidity and often leading to temporary or permanent cessation of the cancer therapeutics. With their increased use, cardio-oncologists must recognize these toxicities and develop appropriate monitoring and treatment plans. The TKI nilotinib was initially approved as a second line agent for patients with CML however, it is now approved for patients with newly diagnosed disease based on higher 12-month major molecular response rates and reduced progression compared to imatinib in the ENESTnd trial.6 Despite its efficacy, multiple cardiovascular (CV) and metabolic side effects have been identified including hyperglycaemia, hyperlipidaemia and QT prolongation. The vascular side effects have been particularly troublesome however. The 5 year follow-up data from ENESTnd reported rates of ischemic heart disease, cerebrovascular disease or peripheral arterial disease (PAD) at 7.5% for those patients taking nilotinib 300 mg twice daily and 13.4% for those taking 400 mg twice daily. In comparison, only 2.1% of patients in the imatinib group reported these toxicities.7 Similarly, ponatinib, a third generation TKI used for CML, has also shown significantly elevated rates of vascular toxicity. In the median 12 month follow-up data from the PACE trial, rates of ischemic heart disease, cerebrovascular disease and PAD were 6, 3, and 4%, respectively with even higher rates observed after 28 months of follow-up.8,9 As a result of these data, ponatinib was pulled from the market in the United States for a period of time and is now only approved for patients who have failed other therapies for CML or those patients with the T315I mutation. The IMiDs such as thalidomide, lenalidomide, and pomalidomide which are used primarily to treat multiple myeloma and AL amyloidosis all demonstrate increased rates of venous thromboembolism. Furthermore, multiple myeloma patients are at higher risk of arterial thrombo-embolic events regardless of IMiD exposure, though rates are even higher with the use of lenalidomide.10 The incidence of myocardial infarction (MI) and stroke is 1.98 and 3.4%, respectively with the use of lenalidomide and dexamethasone compared to 0.57 and 1.7% with dexamethasone alone.10,11 As a result, lenalidomide carries a black box warning for MI and stroke. The exact mechanism is not clear and increased arterial vascular events are not seen with the other immunomodulation drugs. Accelerated hypertension is also a commonly observed vascular toxicity of angiogenesis inhibitors (AIs), which are a class of TKIs that have activity against the VEGF receptor as well as with the PI, carfilzomib. AIs commonly associated with hypertension include sunitinib, sorafenib, axitinib, and pazopanib which are used in the treatment of a variety of malignancies including renal cell carcinoma.12 VEGF inhibition is also seen as an off-target effect of other TKIs. For example, ponatinib which primarily affects BCR-ABL also blocks VEGF2 signalling with rates of hypertension reported at more than 20%.8,9 Similarly, the reported incidence of hypertension associated with carfilzomib is 14%.13 The aetiology of TKI and IMiD vascular events is unclear and remains an area of active investigation. These may be due to accelerated atherosclerosis, vasospasm or embolic phenomena in the setting of underlying endothelial dysfunction.8 The pathophysiology of AI- and PI-induced hypertension is likely due to decreased nitric oxide (NO) production leading to vasoconstriction either from VEGF inhibition or via direct effects on nitric oxide synthase and NO homeostasis.14,15 Other postulated mechanisms of AI induced hypertension include microvascular rarefaction (decreased peripheral capillary density) or the production of vasoactive substances (i.e. sFlt-1 and endothelin 1).12,16 Patients with traditional CV risk factors are more likely to experience these vascular complications. While there are no specific guidelines for monitoring or treating patients receiving these therapies, expert recommendations have recently been published regarding nilotinib and ponatinib. Patients treated with these agents should receive thorough CV assessment, including physical examination, lipid panel, fasting glucose, electrocardiogram and ankle-brachial index (ABI) at the start of therapy, with reassessment after 3–6 months. CV medical therapy should be initiated if clinically indicated.8 ABIs are both non-invasive and inexpensive making them a particularly useful screening tool in this population given the high rates of peripheral vascular disease. In a study of 159 patients, the relative risk of an abnormal ABI in patients treated with nilotinib compared to imatinib was 10.3.17 Patients receiving IMiDs frequently receive antithrombotic prophylaxis against venous thromboembolism (VTE) however there are no clear recommendations regarding the choice of therapy or guidelines regarding arterial thrombo-embolic prevention.10 For patients that experience accelerated hypertension, ACE inhibitors and dihydropyridine calcium channel blockers are frequently utilized as first line therapies, however nitric oxide donating medications may be important adjuvant options.12,18 Arrhythmias, particularly atrial fibrillation (AF) are quite common in cancer patients, and it is an increasingly recognized cardiotoxicity of TKI therapy.19 Ibrutinib is a TKI with activity against Bruton’s tyrosine kinase (BTK) and TEC proteins, approved for the treatment of chronic lymphocytic leukaemia (CLL), mantle cell lymphoma and Waldenstrom’s macroglobulinaemia. Rates of atrial fibrillation are reported between 3.5 and 10.8%.20,21 Ibrutnib’s effects on BTK as well as the PI3K-AKT signalling pathway may play an important role in the development of AF. Studies evaluating both mouse and human myocytes have confirmed an association between decreased PI3K-AKT activity and atrial fibrillation.22,23 These observations are not sufficient to explain the increased rates of AF with ibrutinib as the more selective second generation BTK inhibitor acalabrutinib has not demonstrated an increased incidence of AF.24 Ibrutinib is also associated with increased bleeding complications including a 2% incidence of subdural hematomas.25 Therefore, initiating anticoagulation to reduce AF associated stroke can be challenging, and rhythm control strategies may be contraindicated. Recently, there has been substantial growth in the field of immunotherapy with dramatic results being reported for many cancers. IL-2 therapy for metastatic melanoma and renal cell carcinoma has been available for several decades, and is now used in combination with adoptive cell therapy. Toxicities are frequently related to cytokine release and capillary leak syndrome leading to arrhythmias (AF reported at more than 10%) and significant hypotension. Myocardial ischemia has also been reported in 3–9% of patients treated with high dose IL-2, while 1–4% had documented infarction.26–28 Underlying coronary artery disease may pre-dispose to these toxicities however recent data suggests that these episodes of myocardial injury may not be due to ischemic coronary disease but rather direct myocardial inflammation/myocarditis.29 Programmed cell death protein-1 (PD1) functions as an immune checkpoint protein, down-regulating pathways that affect T cell mediated inflammation. PD1 inhibitors are now being evaluated for several malignancies with promising results.5 PD1 is also present in cardiac myocytes, and its inhibition may lead to an increased risk of myocarditits.30 Thus far, reports of myocarditis with PD1 inhibitors have been rare, however this toxicity may become more recognized and prominent with their increased use. With the changing landscape of cancer therapeutics, patients are living longer and in many cases surviving their malignancy. Despite these advances, cardiovascular toxicity remains a significant cause of morbidity and mortality in cancer patients and survivors and the field of cardio-oncology has developed to meet the needs of this growing patient population. While the cardio-oncologist must still be familiar with anthracyclines and other traditional chemotherapies, it is evident that there is a shifting emphasis to targeted and immunotherapies in the treatment of many cancers. Cardiovascular complications are no longer limited just to heart failure, and cardio-oncologists must be familiar with the wide variety of cardiotoxicities associated with these novel agents to ensure the health and safety of their patients. References are available as supplementary material at European Heart Journal online.
No takes yet. Share an insight, caveat, or question.
Michael G. Fradley (2016) conducted a review in Cancer and cardiovascular toxicity. Novel cancer therapeutics (TKIs, PIs, IMiDs, immunotherapies) was evaluated. Novel cancer therapeutics, including tyrosine kinase inhibitors and immunotherapies, are associated with diverse cardiovascular toxicities such as vascular disease, hypertension, and arrhythmias.
Synapse has enriched 10 related papers. Consider them for comparative context: